ClinicalTrials.gg
RecruitingNCT06528496Updated Aug 28, 2026

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

A Phase 2 interventional study of DANYELZA and Sargramostim in High-risk Neuroblastoma, Neuroblastoma and Childhood Neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Months to 19 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Months to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies testing naxitamab in Neuroblastoma — 9 open to participants now, 12 under way, none of them phase 3. naxitamab · Neuroblastoma.

Planned enrollment
12th of 17
45 · median 62
Started
2024
with 1 other
Phase 2
11 of 17
7 open now
Primary completion
2029-07
later than 8 of 11 live
Registered
13th of 17
by date
Lead sponsor
6 of 17
Memorial Sloan Kettering Cancer Center

Among the 17 studies testing naxitamab in Neuroblastoma, this one is the 12th largest by planned enrollment, is one of 2 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 8 of the 11 other live ones, and was the 13th registered.

Neuroblastoma

676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.

Browse Neuroblastoma studies →

Open to participants now

9 of the 17 studies testing naxitamab in Neuroblastoma are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About naxitamab

naxitamab: first FDA approval 2020 (DANYELZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.

This study: 18 Months to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing naxitamab in Neuroblastoma, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.

03

Conditions studied

  • High-risk Neuroblastoma
  • Neuroblastoma
  • Childhood Neuroblastoma

Browse trials for

Keywords

  • High-risk neuroblastoma
  • neuroblastoma
  • childhood neuroblastoma
  • N10
  • Memorial Sloan Kettering Cancer Center
  • 24-144
04

Who can participate

Ages eligible
18 Months to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of NB as defined by histopathology, BM plus high urine catecholamine levels, or positivity in MIBG scan.
  • HR-NB, defined as MYCN-amplified stage L2/M/MS at any age and stage M in patients >18 months old.
  • No more than one prior cycle of HR-NB chemotherapy
  • Age \<19 years.
  • Signed indicating awareness of the nature of this treatment.

Exclusion criteria

Exclusion Criteria:

  • Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity >/= to grade 3

    °Organ dysfunction due to direct effects of primary tumor or disease, or due to paraneoplastic syndromes associated with neuroblastoma, will not be considered in exclusion criteria. Similarly, complications of interventions to control above direct effects (e.g., - induced hyperglycemia or hypertension) will also not be considered in exclusion criteria

  • Inability to comply with protocol requirements
  • Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Participants with Neuroblastoma

    Participants will receive 4 cycles of induction chemotherapy followed by a response-based intervention.

    Biological: DANYELZA · Biological: Sargramostim · Drug: Cytoxan · Drug: Topotecan · Drug: Vincristine · Drug: Doxorubicin · Drug: Ifosfamide · Drug: Etoposide · Drug: Carboplatin · Drug: Irinotecan · Drug: Temozolomide · Radiation: Radiation Therapy

Interventions

  • BiologicalNaxitamabStudies of NaxitamabNaxitamab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    DANYELZA is a humanized monoclonal antibody of the IgG1 subclass

    Also known as: Naxitamab

  • BiologicalSargramostim

    Yeast derived recombinant human Sargramostim (GM-CSF)

    Also known as: granulocyte-macrophage colony-stimulating factor, GM-CSF

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclophosphamide is an alkylating agent related to nitrogen mustard

    Also known as: Cyclophosphamide

  • Topotecan is a topoisomerase I-inhibitor that is a semisynthetic derivative of camptothecin.

  • Vincristine is an alkaloid isolated from Vinca rosea Linn (periwinkle).

    Also known as: Oncovin

  • Doxorubicin is an anthracycline antibiotic

    Also known as: Adriamycin

  • Ifosfamide is a structural analogue of cyclophosphamide

    Also known as: Isophosphamide

  • Etoposide for Injection is available as a 20 mg/mL solution in sterile multiple dose vials (5 mL, 25 mL, or 50 mL each).

    Also known as: VePesid, Etopophos, VP-16

  • Carboplatin is available in 50 mg, 150 mg, 450 mg, and 600 mg vials.

    Also known as: Paraplatin

  • Irinotecan hydrochloride trihydrate (CPT-11) is a topoisomerase I inhibitor

    Also known as: Camptosar

  • Temozolomide is administered intravenously

    Also known as: Temodar

  • RadiationRadiation Therapy

    Between first and second cycle of antibody

06

What researchers measure

Primary outcomes

  1. Evaluate participant response

    To assess the early Complete Response/CR rate in newly-diagnosed HR-NB patients.

    Time frame: After 2 cycles of mAb-based therapy (each cycle is 21 days)

07

Study locations

1 of 1 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Brian Kushner, MD · Contact212-639-6793
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jul 2029, 60 months after the start.

Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's planned 60 months is below that.

Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2024
First posted
Jul 30, 2024
StartActual
Jul 22, 2024
Primary completionEst.
Jul 22, 2029
CompletionEst.
Jul 22, 2029
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06528496
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Jul 22, 2024
Primary completion
Jul 22, 2029 (estimated)
Completion
Jul 22, 2029 (estimated)
Last update
Aug 28, 2026

Study contacts

Brian Kushner, MD
Contact
kushnerb@MSKCC.ORG
8336755491
Fiorella Iglasias Cardenas, MD, MS
Contact
iglesiaf@mskcc.org
Brian Kushner, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naxitamab · Sargramostim · Cyclophosphamide · Topotecan · Vincristine · Doxorubicin · Ifosfamide · Etoposide · Carboplatin · Irinotecan · Temozolomide

Start the discussion